Bryce Point Capital LLC Purchases New Position in TransMedics Group, Inc. $TMDX

Bryce Point Capital LLC purchased a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) during the third quarter, HoldingsChannel.com reports. The firm purchased 6,131 shares of the company’s stock, valued at approximately $688,000. TransMedics Group makes up approximately 0.8% of Bryce Point Capital LLC’s investment portfolio, making the stock its 4th biggest holding.

Other hedge funds also recently modified their holdings of the company. Whittier Trust Co. of Nevada Inc. grew its position in TransMedics Group by 981.0% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after acquiring an additional 206 shares during the last quarter. Salomon & Ludwin LLC bought a new position in TransMedics Group in the 3rd quarter valued at $28,000. Pilgrim Partners Asia Pte Ltd acquired a new position in TransMedics Group in the third quarter worth $40,000. First Horizon Corp bought a new stake in shares of TransMedics Group during the third quarter worth $43,000. Finally, Elevation Point Wealth Partners LLC bought a new stake in shares of TransMedics Group during the second quarter worth $48,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

TMDX has been the topic of several research reports. Morgan Stanley upped their price target on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Needham & Company LLC upped their target price on shares of TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Piper Sandler reissued an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd. Canaccord Genuity Group boosted their price objective on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Finally, Jefferies Financial Group assumed coverage on TransMedics Group in a report on Monday, October 13th. They set a “buy” rating and a $145.00 price objective on the stock. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, TransMedics Group currently has an average rating of “Moderate Buy” and a consensus target price of $144.25.

Insiders Place Their Bets

In related news, insider Anil P. Ranganath sold 3,000 shares of the stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the completion of the sale, the insider directly owned 13,955 shares of the company’s stock, valued at approximately $2,026,545.10. This represents a 17.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Gerardo Hernandez sold 920 shares of TransMedics Group stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total transaction of $128,450.40. Following the completion of the transaction, the chief financial officer directly owned 15,064 shares in the company, valued at approximately $2,103,235.68. The trade was a 5.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 8,920 shares of company stock worth $1,257,310 over the last ninety days. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Trading Up 0.9%

TMDX opened at $136.34 on Tuesday. The firm has a market cap of $4.66 billion, a PE ratio of 55.20 and a beta of 2.06. TransMedics Group, Inc. has a twelve month low of $62.07 and a twelve month high of $156.00. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. The firm’s fifty day moving average is $132.84 and its two-hundred day moving average is $124.80.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.